Is Semaglutide Legal in the UK? MHRA Authorisations Explained

The authorisations that exist — and the boundary that does not move

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analogue of the endogenous incretin hormone GLP-1. Structurally, it resembles the human GLP-1 peptide closely enough to bind its receptor with high affinity, but it carries modifications — including a C18 fatty diacid side chain attached via a linker — that extend its half-life to approximately one week in plasma. That pharmacokinetic profile is what makes a once-weekly dosing schedule clinically viable. The pivotal STEP 1 trial, a randomised, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2021 (Wilding et al., PMID 33567185), reported a mean weight reduction of approximately 14.9% from baseline over 68 weeks in patients receiving semaglutide weekly, versus 2.4% in the placebo group.

That body of clinical evidence produced a cascade of regulatory applications and marketing authorisations worldwide. In the United Kingdom, the regulatory authority responsible for assessing and licensing medicines for human use is the Medicines and Healthcare products Regulatory Agency (MHRA). Since Brexit, the MHRA has operated its own post-market approval pathway, independent of the European Medicines Agency, under the framework established by the Human Medicines Regulations 2012. Understanding semaglutide's legal status in the UK means understanding exactly which products the MHRA has authorised, in what form, and for which indications — and then understanding what sits categorically outside all of them.

Injectable Wegovy — MHRA marketing authorisation, prescription-only

Wegovy is a once-weekly subcutaneous injection of semaglutide, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, dyslipidaemia, type 2 diabetes mellitus, or obstructive sleep apnoea. The MHRA granted Wegovy a Great Britain marketing authorisation following its own scientific assessment. It is classified as a prescription-only medicine (POM) under Schedule 1 of the Prescription Only Medicines Order, meaning it may only be supplied to a patient in response to a written prescription issued by an authorised healthcare professional. A pharmacist cannot dispense it without that prescription, and a patient cannot legally obtain it through any other route in the UK.

The MHRA's public assessment report and product information for Wegovy are available through the agency's medicines database at gov.uk/MHRA. The prescription-only classification is not a procedural formality; it reflects the MHRA's determination that semaglutide at this dose requires individual clinical assessment, carries contraindications and interactions that need professional evaluation, and involves risks including gastrointestinal effects, heart rate changes, and potential associations with thyroid C-cell tumours observed in rodent studies, the clinical significance of which requires monitoring in the context of individual patient risk profiles.

Oral Wegovy — MHRA marketing authorisation, June 2026 (first in Europe)

A tablet formulation of semaglutide at a higher dose, developed for chronic weight management, received MHRA marketing authorisation in June 2026. This marked the first approval anywhere in Europe for an oral GLP-1 receptor agonist in a weight-management indication. The oral formulation incorporates a permeation enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, known as SNAC) that facilitates absorption of semaglutide across the gastric mucosa, a mechanism that differs fundamentally from the enteral absorption pathway of conventional small-molecule oral medicines. The bioavailability achieved is lower than that of the subcutaneous injection, but the clinical data package submitted to the MHRA demonstrated efficacy sufficient to support the indication.

The MHRA's authorisation of oral Wegovy does not make it immediately available to all UK patients. A marketing authorisation establishes that a medicine is safe, efficacious, and manufactured to appropriate quality standards; it does not determine how the National Health Service funds or provides access to it. That is a separate question, addressed through health technology assessment.

NHS access — pending NICE appraisal

In England, routine NHS funding of a newly authorised medicine for a given indication is conditional on a positive technology appraisal by the National Institute for Health and Care Excellence (NICE). NICE assesses clinical and cost effectiveness using a structured methodology, evaluating the incremental cost per quality-adjusted life year (QALY) gained against a threshold that reflects what the NHS considers a reasonable use of finite healthcare resources. Until NICE publishes a positive appraisal guidance recommending a medicine for NHS use, NHS commissioners in England are not routinely required to fund it, and it will not typically appear on GP prescribing systems as an NHS prescription option.

As of July 2026, a NICE health technology appraisal of oral Wegovy for chronic weight management had not been concluded. Scotland, Wales, and Northern Ireland operate their own separate health technology assessment bodies — the Scottish Medicines Consortium (SMC), the All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively — and each reaches its own reimbursement decisions on a separate timetable. Injectable Wegovy had itself gone through a NICE appraisal process and been recommended for restricted NHS use in England under a specialist weight-management pathway; injectable Ozempic carries a separate set of NICE guidance relating to its type 2 diabetes indication. The availability of an NHS prescription for any licensed form of semaglutide ultimately depends on whether the specific product, at the specific dose, for the specific indication, has a current positive NICE guidance in the relevant UK nation.

Patients seeking semaglutide through the NHS should consult their GP or a specialist weight-management service for current prescribing eligibility. Private prescribing is available for licensed medicines through registered private clinics and online prescribing services regulated by the Care Quality Commission (CQC), but private patients should verify that any prescriber is registered with the General Medical Council (GMC) or General Pharmaceutical Council (GPhC) and operating within those bodies' standards for remote prescribing.

The Human Medicines Regulations 2012 and what they prohibit

The legislative basis for medicines regulation in the UK is the Human Medicines Regulations 2012 (SI 2012/1916), a statutory instrument that consolidated and updated earlier pharmaceutical legislation. These regulations govern who may manufacture, import, distribute, and supply medicinal products in the UK, and they establish the marketing authorisation system through which any medicine must be assessed and approved before it can lawfully be placed on the market for human use. The regulations define a "medicinal product" broadly: a substance or combination of substances presented as having properties for treating or preventing disease in human beings, or any substance or combination of substances which may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action.

Under that definition, semaglutide in any presentation — regardless of whether it is a finished pharmaceutical product in a branded pen, or a raw peptide powder sold in a sachet, or a liquid placed in a dropper bottle, or a transdermal patch applied to the skin — constitutes a medicinal product if it is presented or sold in the context of weight management or other therapeutic purposes. A marketing authorisation is required to place such a product on the UK market. The MHRA holds the register of authorised products. If a product containing semaglutide does not appear on that register with a valid current authorisation for the presentation and indication in question, its supply for human use in the UK is unlawful under the regulations.

It is worth being precise about what "unlicensed" means in this context. It does not mean legally ambiguous, unregulated in practice, or tolerated as a grey area. It means that the regulatory pathway required under UK law has not been followed, that the safety and efficacy evidence required to support an authorisation has not been reviewed by the MHRA, and that the quality controls required under Good Manufacturing Practice — controls that govern everything from synthesis conditions to sterility testing to shelf life — have not been assessed or verified by any competent authority. The legal boundary is drawn clearly by the regulations, and it is enforced.

Twenty million doses: the scale of MHRA enforcement in 2025

The MHRA did not merely issue guidance on unlicensed semaglutide in 2025. It seized approximately 20 million doses of unlicensed injectable weight-loss products across enforcement operations conducted during the year. That figure is significant not primarily as a deterrent statistic, but as a diagnostic signal about the nature and scale of the unlicensed market that had developed in response to supply shortages and cost barriers for the licensed products.

The products encountered in those enforcement operations varied considerably. Some were vials labelled as Ozempic or Wegovy that were entirely counterfeit — products packaged to resemble the authorised medicines but manufactured outside the GMP framework, with no guaranteed relationship between label claim and actual content. Some were raw peptide materials packaged in formats intended to suggest a finished pharmaceutical product. Some were sold as "research" or "peptide" vials with nominal labelling, but marketed through social media channels in contexts that made their intended human use unambiguous. The MHRA's enforcement remit covers all of these: the regulatory test is not what a seller calls their product, but what it is and how it is being presented and supplied.

The agency has published public warnings and product alerts through its website at gov.uk/MHRA regarding specific product types encountered in these operations. Those warnings describe real harms that have been associated with unlicensed injectables: products found to contain no semaglutide at all, products with contamination, products with incorrect concentrations, and cases where adverse events reported by patients were traced to unlicensed sources. The 20 million doses seized represent the operational tip of a market the MHRA has characterised as a genuine public health concern.

Formulations that fall outside the authorised landscape

The MHRA's authorisations cover specific products in specific formulations. The existence of those authorisations does not extend legal cover to other presentations of semaglutide by analogy. This is a point of some practical importance, because the unlicensed market has generated a range of alternative formulations that have no counterpart in the authorised landscape.

Powders and raw peptide materials

Raw semaglutide peptide sold as a powder — sometimes labelled as "research grade" or accompanied by a certificate of analysis from a commercial peptide supplier — does not hold a UK marketing authorisation for any human use. The certificate of analysis issued by a commercial peptide supplier is a quality control document for the material as a research chemical; it is not equivalent to, and does not substitute for, the MHRA assessment process. Under the Human Medicines Regulations 2012, presenting or supplying such a material for a medicinal purpose constitutes placing an unauthorised medicinal product on the market.

Oral drops and nasal formulations

Liquid formulations of semaglutide sold in dropper bottles for sublingual or oral administration, or nasal spray formulations, have not received MHRA marketing authorisation. The oral Wegovy tablet authorised in June 2026 is a specific pharmaceutical product developed by Novo Nordisk and assessed by the MHRA as a defined medicine — it is not a category approval that extends to any semaglutide-containing liquid or spray. The SNAC permeation-enhancement technology required for meaningful oral semaglutide bioavailability is a patented, formulation-specific mechanism; a simple aqueous semaglutide solution administered sublingually does not replicate it. Products offering such formulations without a marketing authorisation are unlicensed regardless of any claimed bioavailability benefit.

Transdermal patches

Transdermal patches containing semaglutide have appeared in the unlicensed market. No such product holds an MHRA marketing authorisation. The transdermal delivery of peptide molecules of semaglutide's molecular weight faces substantial pharmacokinetic barriers that have not been addressed through any approved pharmaceutical development programme accepted by the MHRA. These products are unlicensed medicinal products under the Human Medicines Regulations 2012.

The pattern common to all of these unlicensed formulations is the same: a product is presented in the context of weight management or metabolic therapy, containing or claiming to contain semaglutide, without the marketing authorisation that UK law requires and without the quality controls that authorisation entails. The MHRA's enforcement activity applies uniformly across all of them.

What the regulatory picture means in practice

The legal landscape around semaglutide in the UK is more clearly defined than the volume of unlicensed products circulating online might suggest. Injectable Wegovy is a licensed medicine available by prescription. Oral Wegovy is a licensed medicine as of June 2026, pending NHS funding through the NICE process. Ozempic is a licensed medicine for type 2 diabetes. Everything else — the powders, the drops, the patches, the unlicensed vials, the research-grade peptides sold with a wink toward their intended use — sits outside that licensed landscape and is actively subject to MHRA enforcement.

For a person who has a clinical indication for weight management with a GLP-1 receptor agonist, the appropriate pathway is through a licensed healthcare professional who can assess eligibility, contraindications, and the relative merits of NHS versus private prescribing options. That pathway produces a legal, quality-assured medicine from a regulated supply chain. The unlicensed alternatives produce neither of those assurances. The 20 million doses the MHRA seized in 2025 represent the consequences of a market that has grown around the gap between the two.

Summary: the MHRA authorisations, precisely stated

Semaglutide is legal in the UK in specific, authorised forms. Injectable Wegovy (semaglutide, subcutaneous, once weekly) holds MHRA marketing authorisation as a prescription-only medicine for chronic weight management and has been recommended by NICE for a restricted specialist NHS pathway. Oral Wegovy received MHRA marketing authorisation in June 2026, the first such approval in Europe, with NHS availability contingent on a pending NICE health technology appraisal. Injectable Ozempic holds separate MHRA authorisation for the treatment of type 2 diabetes mellitus.

Outside of those specific authorised products, semaglutide in any form — raw peptide, unlicensed injectable, oral drops, transdermal patches — does not hold a UK marketing authorisation, falls outside the Human Medicines Regulations 2012, and is subject to active MHRA enforcement. The agency's seizure of approximately 20 million doses from the unlicensed market in 2025 is the most direct measure available of the scale at which that boundary is being tested and defended. The legal position is not ambiguous. The authorised route to semaglutide in the UK is through a licensed prescriber and a regulated pharmacy.